Print

AVEG 002A

A Phase I Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination with Soluble Recombinant Envelope Vaccine

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) May 06, 1991
HIVAC-1e Env gp160 B
HIVAC-1e Viral Vector - Pox
USA 35
NCT00000630
http://clinicaltrials.gov/ct2/show/NCT00000630